A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics

Abstract Antibiotics are failing fast, and the development pipeline remains alarmingly dry. New drug research and development is being urged by world health officials, with new antibacterials against multidrug-resistant Gram-negative pathogens as the highest priority. Antivirulence drugs, which inhi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anthony D. Verderosa, Rabeb Dhouib, Yaoqin Hong, Taylah K. Anderson, Begoña Heras, Makrina Totsika
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/f60ac0fa11174aadb855edb3235d16e7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!